CRBU Q4 2025 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+89.7% YoY

Gross Profit

$3M82.7% margin

Operating Income

-$28M-722.0% margin

Net Income

-$26M-672.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+79.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$180M

Total Liabilities

$57M

Stockholders' Equity

$122M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+89.7%
Gross Profit	$3M	-$28M	+111.7%
Operating Income	-$28M	-$39M	+26.8%
Net Income	-$26M	-$35M	+25.4%

Revenue Segments

Reportable Segment

$4M100%

Geographic Segments

UNITED STATES

$4M96%

Non-US

$170,0004%